1. Home
  2. TBPH vs NPB Comparison

TBPH vs NPB Comparison

Compare TBPH & NPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • NPB
  • Stock Information
  • Founded
  • TBPH 2013
  • NPB 1999
  • Country
  • TBPH United States
  • NPB United States
  • Employees
  • TBPH N/A
  • NPB N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • NPB
  • Sector
  • TBPH Health Care
  • NPB
  • Exchange
  • TBPH Nasdaq
  • NPB NYSE
  • Market Cap
  • TBPH 464.5M
  • NPB 449.1M
  • IPO Year
  • TBPH N/A
  • NPB 2025
  • Fundamental
  • Price
  • TBPH $10.92
  • NPB $14.07
  • Analyst Decision
  • TBPH Strong Buy
  • NPB Buy
  • Analyst Count
  • TBPH 5
  • NPB 2
  • Target Price
  • TBPH $16.60
  • NPB $17.25
  • AVG Volume (30 Days)
  • TBPH 366.7K
  • NPB 187.1K
  • Earning Date
  • TBPH 08-04-2025
  • NPB 01-01-0001
  • Dividend Yield
  • TBPH N/A
  • NPB 0.70%
  • EPS Growth
  • TBPH N/A
  • NPB 273.19
  • EPS
  • TBPH N/A
  • NPB 1.94
  • Revenue
  • TBPH $65,266,000.00
  • NPB $195,582,000.00
  • Revenue This Year
  • TBPH $43.18
  • NPB $27.37
  • Revenue Next Year
  • TBPH N/A
  • NPB $13.48
  • P/E Ratio
  • TBPH N/A
  • NPB $7.33
  • Revenue Growth
  • TBPH 6.11
  • NPB N/A
  • 52 Week Low
  • TBPH $7.44
  • NPB $11.43
  • 52 Week High
  • TBPH $11.82
  • NPB $14.98
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 60.52
  • NPB N/A
  • Support Level
  • TBPH $10.46
  • NPB N/A
  • Resistance Level
  • TBPH $11.44
  • NPB N/A
  • Average True Range (ATR)
  • TBPH 0.27
  • NPB 0.00
  • MACD
  • TBPH -0.01
  • NPB 0.00
  • Stochastic Oscillator
  • TBPH 56.65
  • NPB 0.00

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About NPB NORTHPOINTE BANCSHARES INC

Northpointe Bancshares Inc operates its business through its wholly-owned banking subsidiary, Its lending focus is the origination of residential mortgages throughout the United States. The majority of these loans are sold in the secondary market through a network of investors. The Company has also developed mortgage advance program that provides funding to pre-approved mortgage bankers who originate and sell individual conforming and non-qualified loan products in the secondary market. The Company continues to service loans that were originated and sold to investors as well as loans held in its portfolio which were originated and selectively held in portfolio.

Share on Social Networks: